# Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

> **NCT05714748** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **West China Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Malignant Tumors

## Interventions

- **BIOLOGICAL:** EBV mRNA vaccine

## Key facts

- **NCT ID:** NCT05714748
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714748, "Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05714748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*